These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 15459602)

  • 1. N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up.
    Miner SE; Dzavik V; Nguyen-Ho P; Richardson R; Mitchell J; Atchison D; Seidelin P; Daly P; Ross J; McLaughlin PR; Ing D; Lewycky P; Barolet A; Schwartz L
    Am Heart J; 2004 Oct; 148(4):690-5. PubMed ID: 15459602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous N-acetylcysteine plus high-dose hydration versus high-dose hydration and standard hydration for the prevention of contrast-induced nephropathy: CASIS--a multicenter prospective controlled trial.
    Koc F; Ozdemir K; Kaya MG; Dogdu O; Vatankulu MA; Ayhan S; Erkorkmaz U; Sonmez O; Aygul MU; Kalay N; Kayrak M; Karabag T; Alihanoglu Y; Gunebakmaz O
    Int J Cardiol; 2012 Mar; 155(3):418-23. PubMed ID: 21106264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial of intravenous n-acetylcysteine to prevent contrast induced nephropathy in acute coronary syndromes.
    Jaffery Z; Verma A; White CJ; Grant AG; Collins TJ; Grise MA; Jenkins JS; McMullan PW; Patel RA; Reilly JP; Thornton SN; Ramee SR
    Catheter Cardiovasc Interv; 2012 May; 79(6):921-6. PubMed ID: 21542122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography.
    Oldemeyer JB; Biddle WP; Wurdeman RL; Mooss AN; Cichowski E; Hilleman DE
    Am Heart J; 2003 Dec; 146(6):E23. PubMed ID: 14661012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect.
    Webb JG; Pate GE; Humphries KH; Buller CE; Shalansky S; Al Shamari A; Sutander A; Williams T; Fox RS; Levin A
    Am Heart J; 2004 Sep; 148(3):422-9. PubMed ID: 15389228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of contrast-induced nephropathy with N-acetylcysteine or sodium bicarbonate in patients with ST-segment-myocardial infarction: a prospective, randomized, open-labeled trial.
    Thayssen P; Lassen JF; Jensen SE; Hansen KN; Hansen HS; Christiansen EH; Junker A; Ravkilde J; Thuesen L; Veien KT; Jensen LO
    Circ Cardiovasc Interv; 2014 Apr; 7(2):216-24. PubMed ID: 24714489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial.
    Patti G; Ricottini E; Nusca A; Colonna G; Pasceri V; D'Ambrosio A; Montinaro A; Di Sciascio G
    Am J Cardiol; 2011 Jul; 108(1):1-7. PubMed ID: 21529740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of acetylcysteine in prevention of contrast nephropathy.
    Azmus AD; Gottschall C; Manica A; Manica J; Duro K; Frey M; Bulcão L; Lima C
    J Invasive Cardiol; 2005 Feb; 17(2):80-4. PubMed ID: 15687530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is treatment with N-acetylcysteine to prevent contrast-induced nephropathy when using bicarbonate hydration out of date?
    Heng AE; Cellarier E; Aublet-Cuvelier B; Decalf V; Motreff P; Marcaggi X; Deteix P; Souweine B
    Clin Nephrol; 2008 Dec; 70(6):475-84. PubMed ID: 19049703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous N-acetylcysteine for preventing contrast-induced nephropathy: a randomised trial.
    Carbonell N; Blasco M; Sanjuán R; Pérez-Sancho E; Sanchis J; Insa L; Bodí V; Núñez J; García-Ramón R; Miguel A
    Int J Cardiol; 2007 Jan; 115(1):57-62. PubMed ID: 16814414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate PercutaneouS Coronary Intervention Acute Myocardial Infarction N-ACC) Trial.
    Thiele H; Hildebrand L; Schirdewahn C; Eitel I; Adams V; Fuernau G; Erbs S; Linke A; Diederich KW; Nowak M; Desch S; Gutberlet M; Schuler G
    J Am Coll Cardiol; 2010 May; 55(20):2201-9. PubMed ID: 20466200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abbreviated dosing of N-acetylcysteine prevents contrast-induced nephropathy after elective and urgent coronary angiography and intervention.
    Ochoa A; Pellizzon G; Addala S; Grines C; Isayenko Y; Boura J; Rempinski D; O'Neill W; Kahn J
    J Interv Cardiol; 2004 Jun; 17(3):159-65. PubMed ID: 15209578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of combination therapy of high-dose oral N-acetylcysteine and intravenous sodium bicarbonate hydration with individual therapies in the reduction of Contrast-induced Nephropathy during Cardiac Catheterisation and Percutaneous Coronary Intervention (CONTRAST): A multi-centre, randomised, controlled trial.
    Chong E; Poh KK; Lu Q; Zhang JJ; Tan N; Hou XM; Ong HY; Azan A; Chen SL; Chen JY; Ali RM; Fang WY; Lau TW; Tan HC
    Int J Cardiol; 2015 Dec; 201():237-42. PubMed ID: 26301645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved estimation of glomerular filtration rate by serum cystatin C in preventing contrast induced nephropathy by N-acetylcysteine or zinc--preliminary results.
    Kimmel M; Butscheid M; Brenner S; Kuhlmann U; Klotz U; Alscher DM
    Nephrol Dial Transplant; 2008 Apr; 23(4):1241-5. PubMed ID: 18174269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-acetylcysteine and/or ascorbic acid versus placebo to prevent contrast-induced nephropathy in patients undergoing elective cardiac catheterization: The NAPCIN trial; A single-center, prospective, randomized trial.
    Habib M; Hillis A; Hammad A
    Saudi J Kidney Dis Transpl; 2016 Jan; 27(1):55-61. PubMed ID: 26787567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty.
    Marenzi G; Assanelli E; Marana I; Lauri G; Campodonico J; Grazi M; De Metrio M; Galli S; Fabbiocchi F; Montorsi P; Veglia F; Bartorelli AL
    N Engl J Med; 2006 Jun; 354(26):2773-82. PubMed ID: 16807414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrarenal application of N-acetylcysteine for the prevention of contrast medium-induced nephropathy in primary angioplasty.
    Aslanger E; Uslu B; Akdeniz C; Polat N; Cizgici Y; Oflaz H
    Coron Artery Dis; 2012 Jun; 23(4):265-70. PubMed ID: 22343798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of N-acetylcysteine and aminophylline in preventing contrast-induced nephropathy.
    Kinbara T; Hayano T; Ohtani N; Furutani Y; Moritani K; Matsuzaki M
    J Cardiol; 2010 Mar; 55(2):174-9. PubMed ID: 20206069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acetylcysteine In Diabetes (AID): a randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics.
    Coyle LC; Rodriguez A; Jeschke RE; Simon-Lee A; Abbott KC; Taylor AJ
    Am Heart J; 2006 May; 151(5):1032.e9-12. PubMed ID: 16644332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does N-acetylcysteine reduce the incidence of contrast-induced nephropathy and clinical events in patients undergoing primary angioplasty for acute myocardial infarction?
    Tanaka A; Suzuki Y; Suzuki N; Hirai T; Yasuda N; Miki K; Fujita M; Tanaka T
    Intern Med; 2011; 50(7):673-7. PubMed ID: 21467697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.